Published in Hepatitis Weekly, September 6th, 1999
Alpha interferon (IFN-(alpha)) is the only drug widely used to treat virus carriers, but the response rate ranges around 20 percent. Lamivudine [(-)-(beta)-L-2',3'-dideoxy-3'-thiacytidine], a nucleoside analogue, has now been approved by the U.S. Food and Drug Administration for the treatment of hepatitis B. The administration of lamivudine induces a significant drop in the amount of virus in the serum of most HBV carriers and, unlike alpha interferon, causes no significant side...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.